Copy Link Print Information

Visugromab

(Synonyms: CTL-002)
2 Cited Publications
Revisión del cliente

Based on 2 publication(s) in Google Scholar

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 98.40%
  • No. CAS: 2556646-63-8
  • Peso molecular:144.56 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Visugromab
  • Experimental Validation Results for Visugromab
  • Experimental Validation Results for Visugromab
  • Experimental Validation Results for Visugromab
  • Experimental Validation Results for Visugromab
  • Visugromab Chemical Structure
    Visugromab Chemical Structure
No. CAS: 2556646-63-8
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Visugromab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Visugromab

More
Customer Validation & Images
ELISACell Proliferation/Viability Assay
  • ELISA
  • Cell Proliferation/Viability Assay

Ver todos los productos específicos de isoformas TGF-beta/Smad

More

Ver todos los productos específicos de isoformas TGF-β Receptor

More
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Immobilized GDF-15 Protein, Human (P.pastoris, His, HY-P75170) can bind Visugromab. The EC50 for this effect is 5.159 ng/mL.

  • 1/16

    Flow cytometric analysis of 1X106 HeLa cells with Visugromab (HY-P99100, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.

  • 1/16

    Visugromab purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 May 14. [Abstract]

    Customer Validation
     GDF-15 protein level measured by ELISA in CM following 1h incubation with different concentrations of Visugromab (0.625-20 μg/mL). 20 μg/mL was selected as the effective neutralization concentration.

  • 1/16

    Visugromab purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 May 14. [Abstract]

    Customer Validation
     The quantification of EdU positive nuclei as a percentage of all nuclei for hAdv cultured in control conditions (hAdv) or in the presence of Visugromab (20 μg/ml) in culture medium. Addition of Visugromab directly to hAdv cells culture medium resulted in decreased proliferation rate of the cells.

  • Visugromab Chemical Structure
    1/16
  • Visugromab
  • Immobilized GDF-15 Protein, Human (P.pastoris, His, HY-P75170) can bind Visugromab. The EC50 for this effect is 5.159 ng/mL.
  • Flow cytometric analysis of 1X106 HeLa cells with Visugromab (HY-P99100, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.